Document is current
Any future updates will be listed below
-
Authors
Katakami, Naoto
Mita, Tomoya
Yoshii, Hidenori
Shiraiwa, Toshihiko
Yasuda, Tetsuyuki
Okada, Yosuke
Kurozumi, Akira
Hatazaki, Masahiro
Kaneto, Hideaki
Osonoi, Takeshi
Yamamoto, Tsunehiko
Kuribayashi, Nobuichi
Maeda, Kazuhisa
Yokoyama, Hiroki
Kosugi, Keisuke
Ohtoshi, Kentaro
Hayashi, Isao
Sumitani, Satoru
Tsugawa, Mamiko
Ryomoto, Kayoko
Kato, Ken
Nakamura, Tadashi
Kawashima, Satoshi
Sato, Yasunori
Watada, Hirotaka
Shimomura, Iichiro
,
Komiyama, K.
Shimizu, T.
Kamei, S.
Kinoshita, T.
Shimoda, M.
Saito, M.
Fujiki, N.
Fujita, Y.
Shimizu, S.
Umayahara, Y.
Irie, Y.
Kataoka, R.
Kiyohara, Y.
Ohashi, M.
Ryomoto, K.
Takahi, Y.
Fujishima, Y.
Fujita, Y.
Fukuhara, A.
Fukui, K.
Hosokawa, Y.
Imagawa, A.
Iwahashi, H.
Mukai, K.
Katsura, T.
Kawamori, D.
Kimura, T.
Kobayashi, S.
Kozawa, J.
Kubo, F.
Maeda, N.
Matsuoka, T.
Miyashita, K.
Nakata, S.
Ninomiya, H.
Nishizawa, H.
Okuno, Y.
Otsuki, M.
Sakamoto, F.
Sasaki, S.
Sato, I.
Shimo, N.
Shimomura, I.
Takahara, M.
Takano, T.
Tokunaga, A.
Uno, S.
Yamaoka, M.
Yoneda, S.
Hajime, M.
Koikawa, K.
Kuno, F.
Matsushita, K.
Narisawa, M.
Tanaka, K.
Sugai, K.
Torimoto, K.
-
Funding
Funding for this research was provided by:
Kowa Co., Ltd.
- License Information
-
More Information
Article History
Received: 27 March 2023
Accepted: 5 June 2023
First Online: 22 June 2023
Declarations
:
: The study protocol was approved by the Ethical Review Board of Osaka University Hospital (approval number: 17367, date of approval: 2018/3/29) and the institutional review board of each participating center according to the Ethical Guidelines for Medical and Health Research Involving Human Subjects issued by the Ministry of Health, Labour and Welfare in Japan. The study was conducted in accordance with the Declaration of Helsinki of 1964 (revised in 2013), the Ethical Guidelines for Medical and Health Research Involving Human Subjects, and other current legal regulations in Japan. Informed consent was obtained from all patients for inclusion in the study.
: Not applicable.
: Naoto Katakami was a staff member of the endowed chair established by funds from Kowa Co. Ltd. and has received lecture fees from Astellas Pharma Inc., AstraZeneca K.K., Daiichi Sankyo Inc., Eli Lilly Japan K. K, Kowa Company Ltd., Kyowa Hakko Kirin Co. Ltd., Mitsubishi Tanabe Pharma Co., Nippon Boehringer Ingelheim Co., Novartis Pharmaceuticals, Novo Nordisk Pharma, Ono Pharmaceutical Co., Taisho Toyama Pharmaceutical Co., Takeda Pharmaceutical Co., Teijin Pharma, Sanofi-Aventis, and Sumitomo Pharma Co. Tomoya Mita has received lecture fees from Kissei Pharmaceutical Co., Ltd., Kowa Pharmaceutical Co., Ono Pharmaceutical Co., Ltd., and Teijin Pharma Company, scholarship donations from MSD K.K., Astellas Pharma Inc., AstraZeneca K.K., Ono Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co. Ltd., Sanofi-Aventis K.K., Daiichi Sankyo Company, Limited, Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Company Limited, Mitsubishi Tanabe Pharma Corporation, Terumo Corporation, Nippon Boehringer Ingelheim Co., Ltd., Novo Nordisk Pharma Ltd., Pfizer Japan Inc., Benefit One Health Care Inc., Mochida Pharmaceutical Co., Ltd., and Nitto Boseki Co., Ltd. as well as endowed chair funding from MSD K.K. and Takeda Pharmaceutical Company Limited. Tetsuyuki Yasuda has received lecture fees from Eli Lilly Japan K.K., Sumitomo Pharma, Novo Nordisk Pharma Ltd., and Teijin Pharma. Yosuke Okada has received lecture fees from MSD K.K., Mitsubishi Tanabe Pharma Corporation, Novo Nordisk Pharma Ltd., Eli Lilly Japan K.K., Novartis Pharmaceuticals Corp., Bayer Holding Ltd., Kowa Pharmaceutical Co. Ltd., Sanofi-Aventis K.K., and Sumitomo Pharma. Hideaki Kaneto has received lecture fees from Nippon Boehringer Ingelheim Co., Ltd., Sanofi-Aventis K.K., Novo Nordisk Pharma Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company, Limited, Mitsubishi Tanabe Pharma Corporation, AstraZeneca K.K., Astellas Pharma Inc., Novartis Pharmaceuticals Co., and Sumitomo Pharma Co.; scholarship donations from Novo Nordisk Pharma Ltd., Nippon Boehringer Ingelheim Co., Ltd., Sumitomo Pharma Co., Ltd., Ono Pharmaceutical Co., Ltd., Sanofi-Aventis K.K., Eli Lilly Japan K.K., Astellas Pharma Inc., Daiichi Sankyo Company, Limited, Mitsubishi Tanabe Pharma Corporation, MSD K.K., Takeda Pharmaceutical Company Limited, AstraZeneca K.K., Mochida Pharmaceutical Co., Ltd., Taisho Pharmaceutical Co., Kissei Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co. Ltd., and Abbott Co. Ltd; and research funding from Taisho Pharmaceutical Co., Sumitomo Pharma Co., and Nippon Boehringer Ingelheim Co., Ltd. Nobuichi Kuribayashi has received lecture fees from Novo Nordisk Pharma Ltd. Satoshi Kawashima has received lecture fees from Sanofi-Aventis K.K., Sumitomo Pharma Co., Kowa Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo Co., and Terumo Corporation. Yasunori Sato has received lecture fees from Mochida Pharmaceutical Co., Ltd, Eisai Co., Ltd., and Eli Lilly and Company. Hirotaka Watada has received honoraria for lectures for Bayer Pharma Japan, Teijin Pharma Ltd., MSD, Sanofi-Aventis K.K., Novo Nordisk, Nippon Boehringer Ingelheim, Eli Lilly, Sumitomo Pharma, Mitsubishi Tanabe Pharma, Daiichi Sankyo Company, Ltd, Abbott, Kowa Co., Ltd., Taisho Pharmaceutical, Astellas Pharma, Kissei Pharmaceutical Co., Ltd., AstraZeneca K.K., Ono Pharmaceutical Co. Ltd. Sanwa Kagaku, Takeda Pharmaceuticals, and research activities for Takeda Pharmaceuticals, Nippon Boehringer Ingelheim, Kissei Pharmaceutical, Novo Nordisk, Mitsubishi Tanabe Pharma, Lifescan Japan, Kyowa Kirin, Sumitomo Pharma, Eli Lilly, Teijin Pharma, Taisho Pharmaceutical, Abbott, Ono Pharmaceutical Co. Ltd., Soiken Inc., Sanwa Kagaku, and Kowa. Iichiro Shimomura has received lecture fees from Amgen Astellas Biopharma K.K., Astellas Pharma Inc., AstraZeneca K.K., Covidien Japan Inc., Daiichi Sankyo Co., Eli Lilly Japan K.K, MSD K.K., KOBAYASHI Pharmaceutical Co., Ltd., Kowa Company, Ltd., Kyowa Kirin Co., Ltd., Takeda Pharma K.K., Mitsubishi Tanabe Pharma Co., Mochida Pharmaceutical Co., Nippon Boehringer Ingelheim Co., Nippon Chemiphar Co., Ltd., Novartis Pharma K.K., Novo Nordisk Pharma, Ono Pharmaceutical Co., Rohto Pharmaceutical Co., Ltd., Sanofi K.K., Sanwa Kagaku Kenkyusho Co., Sumitomo Pharma Co., Taisho Pharmaceutical Co. Ltd., Teijin Pharma,; and research funds from Astellas Pharma Inc., Cancerscan Inc., Daiichi Sankyo Co., Dainippon Sumitomo Pharma Co., Eli Lilly Japan K.K, Japan Agency for Medical Research and Development (AMED), Kaken Pharmaceutical Co., KOBAYASHI Pharmaceutical Co., Ltd., Kowa Company, Ltd., Kubarahonke Co., Ltd., Kyowa Kirin Co., Ltd., Mitsubishi Tanabe Pharma Co., MSD K.K, Novartis Pharma K.K., Novo Nordisk Pharma, Ono Pharmaceutical Co., Rohto Pharmaceutical Co., Ltd. Sanofi K.K., Shionogi & Co., Takeda Pharma K.K., Teijin Pharma; and scholarship donations from Daiichi Sankyo Co., Kowa Company, Ltd., Mitsubishi Tanabe Pharma Co., Mochida Pharmaceutical Co., Novo Nordisk Pharma, Sumitomo Pharma Co., Takeda Pharma K.K., and Teijin Pharma. Hidenori Yoshii, Toshihiko Shiraiwa, Akira Kurozumi, Masahiro Hatazaki, Takeshi Osonoi, Tsunehiko Yamamoto, Kazuhisa Maeda, Hiroki Yokoyama, Keisuke Kosugi, Ketaro Ohtoshi, Isao Hayashi, Satoru Sumitani, Mamiko Tsugawa, Kayoko Ryomoto, Ken Kato, and Tadashi Nakamura declare that they have no conflict of interest.
